Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 23 | 2026 | 870 | 6.940 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2026 | 194 | 3.850 |
Why?
|
| Methotrexate | 10 | 2026 | 348 | 3.740 |
Why?
|
| Neurotoxicity Syndromes | 5 | 2026 | 73 | 3.350 |
Why?
|
| Cerebellar Neoplasms | 8 | 2024 | 316 | 2.740 |
Why?
|
| Medulloblastoma | 7 | 2024 | 376 | 2.540 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2026 | 149 | 2.460 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 211 | 1.940 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 58 | 1.570 |
Why?
|
| Cancer Survivors | 10 | 2025 | 273 | 1.470 |
Why?
|
| Metabolome | 3 | 2025 | 325 | 1.460 |
Why?
|
| Metabolomics | 4 | 2025 | 499 | 1.460 |
Why?
|
| Overweight | 5 | 2022 | 381 | 1.440 |
Why?
|
| Firefighters | 4 | 2016 | 30 | 1.380 |
Why?
|
| Superoxide Dismutase | 2 | 2026 | 173 | 1.330 |
Why?
|
| Child | 48 | 2026 | 26169 | 1.260 |
Why?
|
| Child, Preschool | 31 | 2026 | 15002 | 1.130 |
Why?
|
| Cisplatin | 5 | 2025 | 274 | 1.090 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2026 | 2825 | 1.080 |
Why?
|
| Neoplasms | 8 | 2025 | 2979 | 1.080 |
Why?
|
| DNA Methylation | 6 | 2020 | 1075 | 0.980 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 42 | 0.910 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 55 | 0.900 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 38 | 0.860 |
Why?
|
| Adolescent | 29 | 2026 | 20797 | 0.860 |
Why?
|
| Obesity | 6 | 2020 | 2397 | 0.860 |
Why?
|
| Antineoplastic Agents | 7 | 2026 | 1800 | 0.840 |
Why?
|
| Male | 46 | 2026 | 64378 | 0.830 |
Why?
|
| Proton Therapy | 2 | 2024 | 155 | 0.800 |
Why?
|
| Prognosis | 13 | 2026 | 4851 | 0.780 |
Why?
|
| Brain Neoplasms | 5 | 2025 | 1305 | 0.770 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 154 | 0.750 |
Why?
|
| Survivors | 4 | 2022 | 345 | 0.730 |
Why?
|
| Lipids | 1 | 2026 | 559 | 0.730 |
Why?
|
| Weight Loss | 3 | 2016 | 535 | 0.730 |
Why?
|
| Humans | 62 | 2026 | 130066 | 0.720 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 1827 | 0.700 |
Why?
|
| Female | 41 | 2026 | 70239 | 0.700 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 28 | 0.690 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2021 | 4 | 0.670 |
Why?
|
| Hypothyroidism | 1 | 2021 | 71 | 0.660 |
Why?
|
| Down Syndrome | 2 | 2022 | 233 | 0.640 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 27 | 0.620 |
Why?
|
| Bone Marrow | 1 | 2021 | 317 | 0.610 |
Why?
|
| Infant | 16 | 2026 | 13266 | 0.590 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 199 | 0.580 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 336 | 0.570 |
Why?
|
| Biomarkers | 3 | 2026 | 3357 | 0.560 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 221 | 0.550 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 286 | 0.540 |
Why?
|
| Neonatal Screening | 1 | 2020 | 204 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 142 | 0.530 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 57 | 0.510 |
Why?
|
| Young Adult | 14 | 2026 | 9981 | 0.510 |
Why?
|
| Weight Gain | 2 | 2019 | 385 | 0.510 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.500 |
Why?
|
| Hearing Loss | 3 | 2025 | 203 | 0.490 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 521 | 0.470 |
Why?
|
| Ear Diseases | 1 | 2015 | 23 | 0.460 |
Why?
|
| DNA | 1 | 2020 | 1398 | 0.430 |
Why?
|
| Follow-Up Studies | 9 | 2026 | 5167 | 0.410 |
Why?
|
| Mucositis | 2 | 2024 | 20 | 0.400 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 3407 | 0.390 |
Why?
|
| Genome, Human | 1 | 2020 | 1318 | 0.380 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 461 | 0.380 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17537 | 0.360 |
Why?
|
| Health Status | 1 | 2014 | 371 | 0.360 |
Why?
|
| Fatigue | 3 | 2022 | 191 | 0.350 |
Why?
|
| Cranial Irradiation | 3 | 2025 | 71 | 0.330 |
Why?
|
| Genetic Variation | 3 | 2019 | 1544 | 0.330 |
Why?
|
| Case-Control Studies | 6 | 2026 | 3349 | 0.310 |
Why?
|
| Body Mass Index | 5 | 2020 | 1694 | 0.310 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 952 | 0.300 |
Why?
|
| Risk Factors | 10 | 2026 | 10959 | 0.280 |
Why?
|
| Hypospadias | 2 | 2020 | 78 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 163 | 0.280 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 1393 | 0.260 |
Why?
|
| Incidence | 4 | 2022 | 3321 | 0.250 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 306 | 0.230 |
Why?
|
| Human Growth Hormone | 1 | 2025 | 73 | 0.220 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.220 |
Why?
|
| Machine Learning | 2 | 2025 | 379 | 0.210 |
Why?
|
| Growth Disorders | 1 | 2025 | 181 | 0.210 |
Why?
|
| Creatinine | 2 | 2023 | 396 | 0.210 |
Why?
|
| Cochlea | 1 | 2024 | 86 | 0.210 |
Why?
|
| Adult | 14 | 2025 | 31012 | 0.210 |
Why?
|
| Genotype | 3 | 2020 | 2587 | 0.200 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 201 | 0.200 |
Why?
|
| Constipation | 1 | 2024 | 131 | 0.200 |
Why?
|
| Counselors | 1 | 2023 | 23 | 0.200 |
Why?
|
| Forecasting | 2 | 2022 | 349 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.190 |
Why?
|
| Intelligence | 1 | 2023 | 101 | 0.190 |
Why?
|
| Logistic Models | 2 | 2026 | 1794 | 0.190 |
Why?
|
| Neutropenia | 1 | 2024 | 209 | 0.190 |
Why?
|
| Cultural Competency | 1 | 2023 | 50 | 0.190 |
Why?
|
| Censuses | 1 | 2022 | 9 | 0.180 |
Why?
|
| Asparaginase | 1 | 2022 | 53 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2025 | 288 | 0.180 |
Why?
|
| Genetic Counseling | 1 | 2023 | 237 | 0.180 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 102 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 365 | 0.170 |
Why?
|
| Growth Hormone | 1 | 2021 | 129 | 0.170 |
Why?
|
| Protons | 1 | 2021 | 94 | 0.170 |
Why?
|
| Patch Tests | 1 | 2021 | 7 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 139 | 0.170 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 217 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 5036 | 0.170 |
Why?
|
| Executive Function | 1 | 2021 | 122 | 0.170 |
Why?
|
| Erythema | 1 | 2021 | 29 | 0.170 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.160 |
Why?
|
| Texas | 3 | 2026 | 3655 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 513 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 229 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 756 | 0.150 |
Why?
|
| Biliary Atresia | 1 | 2023 | 224 | 0.150 |
Why?
|
| Hypersensitivity | 1 | 2022 | 226 | 0.150 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 34 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 191 | 0.150 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 44 | 0.150 |
Why?
|
| Age Factors | 4 | 2024 | 2822 | 0.150 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 248 | 0.150 |
Why?
|
| Depression | 2 | 2025 | 1313 | 0.150 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 17 | 0.150 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 146 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 74 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2020 | 146 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 116 | 0.150 |
Why?
|
| Device Removal | 1 | 2021 | 222 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 132 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1004 | 0.140 |
Why?
|
| Self Report | 2 | 2026 | 552 | 0.140 |
Why?
|
| Transportation | 1 | 2018 | 26 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 192 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2019 | 246 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2022 | 1439 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 374 | 0.140 |
Why?
|
| SEER Program | 1 | 2019 | 213 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1282 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2020 | 293 | 0.140 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 156 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 373 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2019 | 730 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 117 | 0.130 |
Why?
|
| Social Class | 1 | 2019 | 213 | 0.130 |
Why?
|
| Adiposity | 2 | 2020 | 209 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 345 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 902 | 0.130 |
Why?
|
| Neutrophils | 1 | 2019 | 362 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 19 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 92 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 426 | 0.120 |
Why?
|
| Recurrence | 1 | 2020 | 1475 | 0.120 |
Why?
|
| Computational Biology | 1 | 2021 | 860 | 0.120 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2107 | 0.120 |
Why?
|
| Middle Aged | 4 | 2019 | 28314 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 282 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2015 | 24 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2018 | 278 | 0.110 |
Why?
|
| Registries | 1 | 2022 | 1607 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 888 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 392 | 0.110 |
Why?
|
| Prevalence | 2 | 2022 | 2687 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2014 | 94 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1800 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1273 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2020 | 6401 | 0.090 |
Why?
|
| Counseling | 1 | 2014 | 236 | 0.090 |
Why?
|
| United States | 5 | 2025 | 11893 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1582 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 820 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1931 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3782 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 538 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 1674 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 439 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2019 | 2400 | 0.080 |
Why?
|
| Pediatrics | 1 | 2019 | 1242 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8545 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3114 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 337 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2025 | 3678 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 123 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 62 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2025 | 393 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 43 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 201 | 0.040 |
Why?
|
| Demography | 1 | 2022 | 237 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 234 | 0.040 |
Why?
|
| Homozygote | 1 | 2023 | 533 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 232 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 354 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 430 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 50 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 58 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1153 | 0.040 |
Why?
|
| Physical Phenomena | 1 | 2018 | 3 | 0.040 |
Why?
|
| Motor Vehicles | 1 | 2018 | 10 | 0.040 |
Why?
|
| Automation | 1 | 2018 | 65 | 0.040 |
Why?
|
| Vehicle Emissions | 1 | 2018 | 21 | 0.040 |
Why?
|
| Exome | 1 | 2023 | 1061 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 88 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 609 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 613 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 563 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 190 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1212 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1210 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1117 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1589 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 679 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2014 | 29 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2014 | 61 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1208 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2322 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3712 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 339 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1325 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1584 | 0.020 |
Why?
|